Organic compounds -- part of the class 532-570 series – Organic compounds – Cyclopentanohydrophenanthrene ring system containing
Reexamination Certificate
2002-06-06
2004-11-02
Qazi, Sabiha (Department: 1616)
Organic compounds -- part of the class 532-570 series
Organic compounds
Cyclopentanohydrophenanthrene ring system containing
C540S543000, C514S172000, C514S177000, C514S169000
Reexamination Certificate
active
06812358
ABSTRACT:
BACKGROUND OF THE INVENTION
Estra-3-keto-4,9(10)-diene steroids (all steroids herein have the natural stereochemistry unless otherwise defined), the products of this invention, are known valuable intermediates to biologically active substances (see G. Teutsch in
Adrenal Steroid Antagonism,
5d. M. K. Agarwal, W. deGruyter and G. Berlin, 1984, pp. 43-75). U.S. Pat. No. 3,461,118 prepares this 3-keto-4,9(10)-diene structural feature from a 3-keto-&Dgr;5(10)-steroid by a process using bromine and pyridine. In the patent, the 3-keto-&Dgr;5(10)-steroid is produced by hydrolysis of the corresponding ketal, but it also can be made by many chemical routes (see CAN 69:77598; NL 6608779), most prominent among them by a Birch reduction of the 3-protected estrone followed by hydrolysis (see CAN 66:65723, NL 6607002).
In French Patent 1,568,711, this same 3-keto starting material, estra-5(10)-ene-3-one steroid, is converted into the subject estra-3-keto-4,9(10)-diene steroids, by a chlorination or iodination process as well as a process of epoxidation, epoxide opening under strongly basic conditions (i.e. potassium hydroxide in refluxing methanol), to produce the 10-hydroxy-estra-4-ene-3,17-dione which is an intermediate of the present invention. This intermediate is carried on by methane sulfonate ester formation followed by treatment with sodium acetate in acetic acid, a process very different from the present invention, and using a starting material different from the present invention.
SUMMARY OF THE INVENTION
The following Chart A illustrates the process of the invention, including the steroid structures and functional group variations. Chart B illustrates steroid structures related to those shown in Chart A.
Disclosed are steroidal epoxides (II) of estra-5(10)-ene-3,17-dione-3,17-bis-ketals (I), specifically 7&agr;-methyl-5(10)-oxido-estra-3,17-dione steroids (IIA), 10-hydroxy-estra-4-ene-3-one steroids (III), and 5,10-dihydroxy-estra-3-one steroids (IV). Also disclosed is a process for preparation of a steroid having the 4,9(10)-diene-3-one structure (VA) by contacting a 10-hydroxy-4-ene-3-ketosteroid (IIIA) and/or a 5,10-dihydroxy-3-ketosteroid (IVA) with concentrated sulfuric acid or moderated sulfuric acid. Further disclosed is a process for preparing estra-3-keto-4,9(10)-diene steroids (V) starting with estra-5(10)-ene-3,17-dione-3,17-bis-ketals (I), derivable from 19-nor-androst-4-ene-3-one steroids, comprising contacting (a) &Dgr;5(10)-bis-ketals (I) with an epoxidizing agent to prepare epoxides (II), (b) contacting the epoxides (II) with dilute acid to produce hydroxy compounds (III) and (IV), and (c) contacting the hydroxy compounds (III) and (IV) with concentrated sulfuric acid. Also disclosed is a process for preparation of steroidal estra-4,9(10)-diene-3,17-diones of structure (V) by treatment of steroidal estra-5(10),9(11)-diene-3,17-diones of structure (VI) with concentrated mineral acid.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
The estra-5(10)-ene-3,17-dione-3,17-bis-ketals (I), the starting materials for the process of the invention, are known in the art: for examples see John F. Templeton et al., J. Chem. Soc., Perkin Trans. 1 (1994), (9), 1149-58; and C. Djerassi, et al., J. Am. Chem. Soc., vol. 81, p 3120 (1959). As shown in Chart A, these &Dgr;5(10)-bis-ketals (I) are typically derived from the readily available 19-nor-androst-4-ene-3-one steroids by standard ketalization methods. Of the many ketals possible, it is preferred that the ketal be derived from ethylene glycol or neopentyl glycol, the latter most preferred.
The structure and functional group variations of the &Dgr;5(10)-bis-ketals (I) are shown in the chart. Some nonlimiting examples of preferred &Dgr;5(10)-bis-ketals (I) for use in the invention include 7&agr;-methyl-estra-5(10)-ene-3,17-dione-3,17-bis-ethylene glycol ketal, 7&agr;-methyl-estra-5(10)-ene-3,17-dione-3,17-bis-neopentyl glycol ketal, and estra-5(10)-ene-3,17-dione-3,17-bis-neopentyl glycol ketal.
As shown in Chart A, the estra-5(10)-ene-3,17-dione-3,17-bis-ketals (I) are epoxidized to produce bis ketal-5(10)-epoxide products (II). Epoxidation of olefins is a standard reaction in organic chemistry (see Fieser and Fieser,
Reagents for Organic Synthesis,
Vol. 1-20, John Wiley & Sons, Inc., N.Y. 1967-2000), but epoxidation of the olefin in &Dgr;5(10)-bis-ketals (I) has not been reported, nor have the requisite epoxide products (II) been reported. Many epoxidizing agents may be used, but preferred is the use of m-chloroperbenzoic acid or peracetic acid in solvents that do not react with peracids, such as methylene chloride. The epoxidizing reaction can be conducted under a wide range of temperatures, but preferred is 0° C. to ambient. The bis-ketal-5(10)-epoxide products (II) are isolated in high conversion by a standard workup, and generally need no further purification by crystallization or chromatography.
The structure and functional group variations of the bis-ketal-5(10)-epoxides (II) are shown in the chart. In some preferred embodiments of the structure, X=C(CH
3
)
2
and R
1
=CH
3
, R
2
=R
3
=H. Some nonlimiting examples of preferred bis-ketal-5(10)-epoxides (II) for use in the invention include 7&agr;-methyl-5(10)-oxido-estra-3,17-dione-3,17-bis-ethylene glycol ketal, 7&agr;-methyl-5(10)-oxido-estra-3,17-dione-3,17-bis-neopentyl glycol ketal, and 5(10)-oxido-estra-3,17-dione-3,17-bis-neopentyl glycol ketal.
As shown in Chart B, 7&agr;-methyl-5(10)-oxido-estra-3,17-dione steroids (IIA) is the product from epoxidation of the &Dgr;5(10)-bis-ketals (I) (R
1
=Ch
3
, R
2
=R
3
=H) to the bis-ketal-5(10)-epoxide products (II) (R
1
=Ch
3
, R
2
=R
3
=H) followed by mild acid hydrolysis.
Referring again to Chart A, in a second step of the process, the bis-ketal-5(10)-epoxides (II) are contacted under dilute acidic conditions to effect both ketal hydrolysis and epoxide opening to give mixtures of 10-hydroxy-estra-4-ene-3-ones (III) and 5,10-dihydroxy-estra-3-ones (IV). The ratio of these monohydroxy and dihydroxy products is not important for the purposes of this invention because both are efficiently converted into the estra-4,9(10)-diene-3-ones (V), the end product of this invention. Many acids and many solvents with water may be used to effect conversion of (II) to (III) and (IV), but preferred are dilute aqueous mineral acids in water miscible solvents such as acetone or tetrahydrofuran. More preferred is contact of the epoxy ketals (II) with ~0.5 M hydrochloric acid in acetone at ambient temperature. The reaction products (III) and (IV) may be isolated by extractive procedures or preferably as a solid by evaporation of the volatile solvent.
The structures and functional group variations of the reaction products (III) and (IV) are shown in the chart. In some preferred embodiments of compounds (III), R
1
=CH
3
, R
2
=R
3
=H; or R
1
=R
2
=R
3
=H. Some nonlimiting examples of preferred 10-hydroxy-estra-4-ene-3-ones (III) for use in the invention include 10-hydroxy-7&agr;-methyl-estra-4-ene-3,17-dione, 10-hydroxy-6&agr;-methyl-estra-4-ene-3,17-dione, and 10-hydroxy-estra-4-ene-3,17-dione. In some preferred embodiments of compounds (IV), R
1
=CH
3
, R
2
=R
3
=H; or R
1
=R
2
=R
3
=H. Some nonlimiting examples of preferred 5,10-dihydroxy-estra-3-ones (IV) for use in the invention include 5,10-dihydroxy-7&agr;-methyl-estra-3,17-dione, 5,10-dihydroxy-6&agr;-methyl-estra-3,17-dione, and 5,10-dihydroxy-estra-3,17-dione.
In the final step of the process (Chart A), the 10-hydroxy-estra-4-ene-3-ones (III) and 5,10-dihydroxy-estra-3-ones (IV) are converted by acidic dehydration to the product of this invention, estra-3-keto-4,9(10)-diene steroids (V). This conversion is surprisingly and unexpectedly specific to concentrated sulfuric acid and slightly moderated forms of sulfuric acid. Other readily available concentrated acids do not efficiently make this conversion. Those acids which give none
Hessler Edward J.
Van Rheenen Verlan H.
Bridge Organics Co.
MacMillan Sobanski & Todd LLC
Qazi Sabiha
LandOfFree
Process for making estra-4,9(10)-diene steroids does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Process for making estra-4,9(10)-diene steroids, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Process for making estra-4,9(10)-diene steroids will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3322198